Pfizer launches new biopharmaceutical company to develop Parkinson’s drugs

News

Author: Simge Eva DoganPublished: 7 November 2018

Prep: Cook: Serves:

Pharmaceutical company Pfizer has teamed with investment firm Bain Capital to launch Cerevel Therapeutics – a biopharmaceutical company focused on developing drugs for Parkinson’s and other central nervous system conditions.

The new company – which will receive US $350 million of investment from Bain Capital – will begin working on phase three clinical trials on a Parkinson’s drug designed to increase levels of dopamine in the brain. Cerevel will also continue to develop several of Pfizer’s drug programmes which closed earlier this year.

Marco Baptista, director of research programmes at The Michael J Fox Foundation – which has partnered with Pfizer since 2010 – said: “This is welcome news for Parkinson’s patients and researchers. Pfizer had developed a diverse group of novel therapeutics for Parkinson’s disease, which are now going to get another chance at success. MJFF looks forward to partnering with Cerevel to support the advancement of these promising programs.”

To read more on this topic click here.

For more information on Parkinson’s treatments please visit the EPDA website

New smart glasses could track Parkinson’s symptoms

Last Month

Next Month

Go Back

Share this story

Comments

Global update

‘Chopsticks are not easy for a person with Parkinson’s’

In the third in our series on this year’s World Parkinson Congress (WPC),

Parkinson’s and depression: it’s not all in your mind

The causes of and treatments for depression and Parkinson’s disease

How New York inspired Copenhagen to walk for Parkinson’s

‘Exercise is medicine’: the Danish Parkinson’s Association’s motto

Could virtual studies support Parkinson’s disease research?

Parkinson’s research is “hampered by inefficient recruitment and burdensome in-person assessments”, according to researchers in the US and Canada. But could virtual research have the potential to help solve some of these problems? Recruiting 203 participants from Fox Insight – an online clinical study sponsored by The Michael J Fox Foundation – the team assessed the validity of the participants’ self-reported Parkinson’s health information, and their willingness to take part in video-based research. Participants completed online questionnaires and attended two virtual visits, with a movement disorder specialist determining the likely diagnosis compared to the self-reported diagnosis. The study revealed that the participants’ self-reported diagnosis of Parkinson’s was accurate – and that 98.5% of participants would consider participating in a future study with virtual visits. The researchers concluded: “Our study demonstrates the promise of a much-needed novel model for conducting Parkinson’s research and highlights the potential of such a model for ……

Gait and tremor may be the best early predictors of Parkinson’s disease

Gait and tremor may be the most identifiable early signs of Parkinson’s disease, according to researchers from the US, France and Germany. The researchers analysed data from two large health-record databases, including an insurance company’s de-identified administrative claims. Selecting 8,382 participants with Parkinson’s disease, the scientists evaluated individual occurrences of reported symptoms over time – and how these corresponded to their Parkinson’s diagnosis. The analysis revealed a “pre-diagnostic window” in which symptoms were reported but no diagnosis of Parkinson’s disease was made. The most dominant symptoms in this pre-diagnostic window were abnormal gait and tremor, highlighting “the existence of a population of [Parkinson’s] patients whose diagnoses can be accelerated”. The researchers concluded: “Accurate, prospective identification of high-risk individuals would allow for earlier diagnosis, intervention and more effective large-scale evaluation of potential therapeutics.”

Air pollution may be linked to greater risk of Parkinson’s disease

A study from researchers in South Korea suggests that exposure to nitrogen dioxide (NO2), a gas associated with car and power plant emissions, could increase the risk of Parkinson’s disease. Using Korean National Health Insurance Service data, the researchers identified 78,830 participants above age 40 who had lived in Seoul during a certain time frame – and had not been diagnosed with Parkinson’s disease before 2006. During the study period of January 2007 to December 2015, 338 of the participants were diagnosed with the condition. The team then used participant addresses to determine the degree of air pollution exposure. The analysis revealed that those with the highest NO2 exposure had a “statistically significant” greater risk of being diagnosed with Parkinson’s disease. “These findings suggest that regulation of air pollutants might reduce the incidence of Parkinson’s disease,” wrote the researchers, “advocating for the need to implement a targeted public health policy.”

All fields required

First name*
Last name*
Email address*
Enter Email Confirm Email
Country of residence*
About me*
- I have Parkinson's disease
- I am a partner / carer / family / friend of someone who has Parkinson's
- I am a healthcare professional with an interest in Parkinson's
- I work for a Parkinson's disease organisation
- Other
CAPTCHA
*
- By proceeding you agree to our
Email
This field is for validation purposes and should be left unchanged.

Pfizer launches new biopharmaceutical company to develop Parkinson’s drugs

News

Author: Simge Eva DoganPublished: 7 November 2018

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Global update

‘Chopsticks are not easy for a person with Parkinson’s’

Special reports

Parkinson’s and depression: it’s not all in your mind

In my country

How New York inspired Copenhagen to walk for Parkinson’s

Could virtual studies support Parkinson’s disease research?

Gait and tremor may be the best early predictors of Parkinson’s disease

Air pollution may be linked to greater risk of Parkinson’s disease

{title}

Subscribe

Pfizer launches new biopharmaceutical company to develop Parkinson’s drugs

News

Author: Simge Eva DoganPublished: 7 November 2018

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Related articles

Global update

‘Chopsticks are not easy for a person with Parkinson’s’

Special reports

Parkinson’s and depression: it’s not all in your mind

In my country

How New York inspired Copenhagen to walk for Parkinson’s

Could virtual studies support Parkinson’s disease research?

Gait and tremor may be the best early predictors of Parkinson’s disease

Air pollution may be linked to greater risk of Parkinson’s disease

{title}

Subscribe

Sign in